Elizabeth Ramsey, PA
Medical · Danville, KYNPI 1477835494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,345, more than ten times the $102 reported in 2021.
Across 276 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$567
- Novo Nordisk$555
- Pfizer$479
- AstraZeneca$371
- Amgen$358
- Biohaven Pharmaceutical Holding Company Ltd.$349
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $567 |
| Novo Nordisk | 31 | $555 |
| Pfizer | 39 | $479 |
| AstraZeneca | 14 | $371 |
| Amgen | 23 | $358 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $349 |
| Phathom Pharmaceuticals, Inc. | 11 | $262 |
| GSK | 13 | $232 |
| Abbott | 14 | $228 |
| Lilly USA, LLC | 13 | $216 |
| Sumitomo Pharma America, Inc. | 10 | $172 |
| Boehringer Ingelheim | 11 | $159 |
| Exact Sciences | 7 | $108 |
| Kowa Pharmaceuticals America, Inc. | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Astellas Pharma US Inc | 5 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Merck | 3 | $38 |
| Inspire Medical Systems, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Verona Pharma, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$154
- AIRSUPRA$125
- VOQUEZNA$120
How this compares
$4,663 in reported general payments places this provider in the 80th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 136 | $173,122 |
| EliquisApixaban | 55 | $64,572 |
| OzempicSemaglutide | 43 | $58,337 |
| MyrbetriqMirabegron | 60 | $43,204 |
| RybelsusSemaglutide | 30 | $42,095 |
| FarxigaDapagliflozin Propanediol | 45 | $34,297 |
| JanuviaSitagliptin Phosphate | 30 | $33,959 |
| XareltoRivaroxaban | 20 | $24,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $20,795 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $18,647 |
| MounjaroTirzepatide | 15 | $14,103 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,834 |
| VascepaIcosapent Ethyl | 12 | $5,434 |
| Dexlansoprazole DrDexlansoprazole | 22 | $4,134 |
| Celecoxib | 62 | $3,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $159 | $173,122136 claims |
| Novo NordiskOzempic, Rybelsus | $555 | $100,43173 claims |
| PfizerEliquis, Paxlovid | $479 | $66,00174 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $43,20460 claims |
| AstraZenecaFarxiga | $371 | $34,29745 claims |
| MerckJanuvia | $38 | $33,95930 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $232 | $28,63031 claims |
| Lilly USA, LLCMounjaro | $216 | $14,10315 claims |
| AbbVieSynthroid | $567 | $2,30272 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 medical providers in Kentucky.
Other medical in Danville
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
- Alexandra HuettLouisville$13K
- Danny ThackerFrankfort$11K
- Jessica FrizzellPaducah$10K
- Terry SmithHazard$10K
- Ashley HenegarGeorgetown$10K
- Rachel CrowleyPaducah$8K
- Allison ScottLexington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.